Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|15|9|966-982

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.15, Iss.9, 2009-03, pp. : 966-982

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Using patient-reported outcome measures as quality indicators in routine cancer care

By Stover Angela M.   Basch Ethan M.  

Cancer, Vol. 122, Iss. 3, 2016-02 ,pp. : 355-357

Blackwell Publishing

Access to resources Recommend Favorite

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile

By  

Current Cancer Drug Targets, Vol. 16, Iss. 5, 2016-06 ,pp. : 415-428

Bentham Science Publishers

Access to resources Recommend Favorite

Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy

By  

Current Pharmaceutical Design, Vol. 6, Iss. 14, 2000-09 ,pp. : 1399-1418

Bentham Science Publishers

Access to resources Recommend Favorite

Patient-Specific Alpha-Particle Dosimetry

By  

Current Radiopharmaceuticals, Vol. 4, Iss. 4, 2011-10 ,pp. : 329-335

Bentham Science Publishers

Access to resources Recommend Favorite

Population Pharmacokinetics of Haloperidol Using Routine Clinical Pharmacokinetic Data in Japanese Patients

By Yukawa E.  

Clinical Pharmacokinetics, Vol. 41, Iss. 2, 2002-01 ,pp. : 153-159

Adis International

Access to resources Recommend Favorite